4-((Benzo[c][1,2,5]oxadiazol-5-ylmethyl)thio)-6-((2-fluorobenzyl)thio)-1,3,5-triazin-2(1H)-one

ID: ALA4559360

PubChem CID: 155558124

Max Phase: Preclinical

Molecular Formula: C17H12FN5O2S2

Molecular Weight: 401.45

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  O=c1nc(SCc2ccc3nonc3c2)nc(SCc2ccccc2F)[nH]1

Standard InChI:  InChI=1S/C17H12FN5O2S2/c18-12-4-2-1-3-11(12)9-27-17-20-15(24)19-16(21-17)26-8-10-5-6-13-14(7-10)23-25-22-13/h1-7H,8-9H2,(H,19,20,21,24)

Standard InChI Key:  BPOVIEGLUKBOOX-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 30  0  0  0  0  0  0  0  0999 V2000
   22.4399   -5.4290    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.4388   -6.2564    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1535   -6.6692    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.8700   -6.2559    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.8672   -5.4254    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1517   -5.0163    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.5851   -6.6673    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   24.5800   -5.0103    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.5770   -4.1853    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   25.2898   -3.7700    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.0009   -4.1827    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   26.7118   -3.7710    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.7129   -2.9457    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   25.9970   -2.5337    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.2800   -2.9471    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   27.4262   -4.1835    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   27.4262   -5.0085    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.9967   -1.7087    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   28.1407   -5.4210    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.1384   -6.2468    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8521   -6.6592    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8507   -5.0087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.5649   -5.4175    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.5686   -6.2452    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.3570   -6.4976    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   30.8407   -5.8257    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   30.3511   -5.1583    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  4  7  1  0
  5  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 10 15  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  1  0
 12 16  1  0
 16 17  1  0
 14 18  2  0
 17 19  1  0
 19 20  1  0
 20 21  2  0
 21 24  1  0
 23 22  1  0
 22 19  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  1  0
 27 23  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA4559360

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 401.45

Molecular Weight (Monoisotopic): 401.0416

AlogP: 3.42

#Rotatable Bonds: 6

Polar Surface Area: 97.56

Molecular Species: ACID

HBA: 8

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 5.53

CX Basic pKa: ┄

CX LogP: 4.30

CX LogD: 3.40

Aromatic Rings: 4

Heavy Atoms: 27

QED Weighted: 0.49

Np Likeness Score: -2.08

References

1. Bergant K, Janežič M, Valjavec K, Sosič I, Pajk S, Štampar M, Žegura B, Gobec S, Filipič M, Perdih A..  (2019)  Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase IIα.,  175  [PMID:31096154] [10.1016/j.ejmech.2019.04.055]

Source

Source(1):

• Scientific Literature